Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Alosaimy, Sara, Jorgensen, Sarah C J, Lagnf, Abdalhamid M, Melvin, Sarah, Mynatt, Ryan P, Carlson, Travis J, Garey, Kevin W, Allen, David, Venugopalan, Veena, Veve, Michael, Athans, Vasilios, Saw, Stephen, Yost, Christine N, Davis, Susan L, Rybak, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060146/
https://www.ncbi.nlm.nih.gov/pubmed/32161775
http://dx.doi.org/10.1093/ofid/ofaa051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060146/
https://www.ncbi.nlm.nih.gov/pubmed/32161775
http://dx.doi.org/10.1093/ofid/ofaa051

Ejemplares similares